News

ChemistryToday Interview with Continuous Flow SME Dr Olivier Dapremont

In this latest issue of tks | publisher, event organiser, media agency #ChemistryToday read an interview with one of our #ContinuousFlow SMEs Dr Olivier Dapremont, Executive Director Process Technologies AMPAC Fine Chemicals an SK pharmteco Company. #SKpharmteco is a world-leader in #ContinousFlowProcessing, Olivier shares his expertise as he talks about #SMB and #batchchromatography sharing many …

ChemistryToday Interview with Continuous Flow SME Dr Olivier Dapremont Read More »

AMPAC Fine Chemicals Announces Expansion of Capabilities in California

AMPAC Fine Chemicals, an SK Pharmteco company, adds additional pharmaceutical development and engineering capabilities with the opening of a new Complex Molecule Chemistry & Engineering Center Rancho Cordova, California, August 24, 2022 AMPAC Fine Chemicals (AFC), an SK pharmteco Company, a leading manufacturer of Active Pharmaceutical Ingredients in the United States, expanded its pharmaceutical manufacturing capabilities …

AMPAC Fine Chemicals Announces Expansion of Capabilities in California Read More »

SK pharmteco’s HPAPI Robust Safety Controls Article in Specialty Chemicals Magazine

Safety First, Quality Always isn’t just a tag line for SK pharmteco and its business units; learn about our High Potency API manufacturing capabilities and robust safety controls both at AMPAC Fine Chemicals an SK pharmteco Company and at our sister site SK biotek Ireland an SK pharmteco Company with an article written by SK …

SK pharmteco’s HPAPI Robust Safety Controls Article in Specialty Chemicals Magazine Read More »

SK pharmteco announces $35m investment in Phase 1 of new expansion plan for SK biotek Ireland’s Swords Campus

SK pharmteco announces $35m investment in Phase 1 of new expansion plan for SK biotek Ireland’s Swords Campus SK pharmteco (SKPT) a global CDMO, part of SK Inc., is pleased to announce $35m investment for the initial phase of an expansion plan for SK biotek Ireland’s Dublin-based pharmaceutical manufacturing plant. This project will provide a …

SK pharmteco announces $35m investment in Phase 1 of new expansion plan for SK biotek Ireland’s Swords Campus Read More »

ChemistryToday C&G Therapy Article by Brian Mullan Head of Development & Innovation

In February’s issue ChemistryToday Brian Mullan Yposkesi’s Head of Development & Innovation has published an article on how C&GT are a fast growing and promising class of medicines, that offer the possibility of curing conditions with a genetic basis, that have few or no other options for patients. Click here to read Brian’s article: https://www.teknoscienze.com/wp-content/uploads/2022/02/Mullan_CO1_2022.pdf

Scroll to Top